Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
1.305
-0.005 (-0.38%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Sonoma Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 21.92 | 19.53 | 14.29 | 12.74 | 13.27 | 12.63 | |
Revenue Growth | 47.00% | 36.68% | 12.20% | -4.05% | 5.10% | -32.21% |
Cost of Revenue | 13.39 | 12.11 | 8.82 | 7.99 | 8.8 | 8.64 |
Gross Profit | 8.53 | 7.42 | 5.47 | 4.75 | 4.48 | 3.99 |
Selling, General & Admin | 7.66 | 7.61 | 7.36 | 7.58 | 8.84 | 9.76 |
Research & Development | 2.27 | 2.27 | 1.81 | 1.87 | 0.21 | 0.13 |
Operating Expenses | 9.93 | 9.88 | 9.18 | 9.45 | 9.05 | 9.88 |
Operating Income | -1.41 | -2.46 | -3.71 | -4.7 | -4.57 | -5.89 |
Interest Expense | - | - | - | - | - | -0.01 |
Currency Exchange Gain (Loss) | 1.3 | 1.45 | 0.24 | -0.83 | -0.69 | -0.58 |
Other Non Operating Income (Expenses) | -2.4 | -2.4 | 0.56 | 0.5 | 0.08 | 0.19 |
EBT Excluding Unusual Items | -2.51 | -3.42 | -2.91 | -5.03 | -5.18 | -6.29 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.15 |
Other Unusual Items | - | - | - | - | - | 0.72 |
Pretax Income | -2.51 | -3.42 | -2.91 | -5.03 | -5.18 | -5.42 |
Income Tax Expense | -0.24 | -0.24 | 0.55 | -0.2 | -0.03 | -0.33 |
Earnings From Continuing Operations | -2.26 | -3.18 | -3.46 | -4.84 | -5.15 | -5.09 |
Net Income | -2.26 | -3.18 | -3.46 | -4.84 | -5.15 | -5.09 |
Net Income to Common | -2.26 | -3.18 | -3.46 | -4.84 | -5.15 | -5.09 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 2 | 2 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 2 | 2 | 1 | 0 | 0 | 0 |
Shares Change | 55.39% | 35.70% | 172.75% | 168.12% | 27.93% | 32.92% |
EPS (Basic) | -1.01 | -1.89 | -2.79 | -10.63 | -30.35 | -38.34 |
EPS (Diluted) | -1.01 | -1.89 | -2.79 | -10.63 | -30.35 | -38.34 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -2.66 | -4.13 | -0.17 | -2.4 | -6.42 | -4.39 |
Free Cash Flow Per Share | -1.19 | -2.45 | -0.14 | -5.28 | -37.84 | -33.06 |
Gross Margin | 38.91% | 37.97% | 38.25% | 37.26% | 33.73% | 31.62% |
Operating Margin | -6.41% | -12.60% | -25.97% | -36.91% | -34.43% | -46.62% |
Profit Margin | -10.33% | -16.26% | -24.20% | -37.97% | -38.81% | -40.28% |
Free Cash Flow Margin | -12.11% | -21.12% | -1.18% | -18.85% | -48.38% | -34.72% |
EBITDA | -1.27 | -2.32 | -3.57 | -4.53 | -4.45 | -5.7 |
EBITDA Margin | -5.80% | -11.89% | -25.00% | -35.53% | -33.49% | -45.15% |
D&A For EBITDA | 0.14 | 0.14 | 0.14 | 0.18 | 0.13 | 0.19 |
EBIT | -1.41 | -2.46 | -3.71 | -4.7 | -4.57 | -5.89 |
EBIT Margin | -6.41% | -12.60% | -25.97% | -36.91% | -34.43% | -46.62% |
Advertising Expenses | - | 0.09 | 0.19 | 0.16 | 0.16 | 0.09 |